Therefore, considering the totality of the evidence reported in this study, it is clear that high CHAC2 expression associates with more progressive disease suggesting a novel therapeutic target for breast cancer as well as a biomarker for the aggressiveness of the breast tumor. Here, CHAC2 is linked to breast carcinoma.